Oral Microbiome Diversity Matters on Nucleos(t)ide Analogue Cessation in Chronic Hepatitis B

1

The study investigates the oral microbiome's role in patients with chronic hepatitis B discontinuing nucleos(t)ide analogue therapy.
2

Higher oral microbiome diversity correlates with favorable outcomes in hepatitis B patients after NUC cessation.
3

Specific oral taxa, such as Prevotella, inversely correlate with hepatitis B surface antigen levels and liver enzymes.
4

The random forest model using oral microbiome markers predicts treatment outcomes better than clinical markers alone.
5

This research highlights the potential of oral microbiome profiling to support prognostication in chronic hepatitis B management.

The Journal Of Infectious Diseases

by Mahin Ghorbani, Agne Kvedaraite, Khaled Al-Manei, Choon Boon Too, Susanne Cederberg, Asgeir Johannessen, Dag Henrik Reikvam, Davide Valentini, Christopher Maucourant, Niklas K Björkström, Soo Aleman, Margaret Sällberg Chen
December 2, 2025

1